A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel ...

T cells are white blood cells that are important for adaptive immunity. They have unique cell surface receptors that are generated by randomly assorting genes. These receptors allow T cells to ...

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced ...

In 2017, the FDA approved a cutting-edge treatment for diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma. It’s called chimeric antigen receptor T-cell therapy, or CAR T ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

Cell morphology describes the shape, size, structure and appearance of a cell, including the arrangement of organelles within the cell. The morphology of a cell is a rich source of information about ...